Order Article Reprints

Theile S, Johansen JS, Nielsen DL, Jensen BV, Hansen CP, Hasselby JP, Eiríksson SV, Chen IM. A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC). Pharmaceutics. 2022; 14(3):509. https://doi.org/10.3390/pharmaceutics14030509

Theile, Susann, Julia Sidenius Johansen, Dorte Lisbet Nielsen, Benny Vittrup Jensen, Carsten Palnæs Hansen, Jane Preuss Hasselby, Sverrir Vídalín Eiríksson, and Inna Markovna Chen. 2022. "A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)" Pharmaceutics 14, no. 3: 509. https://doi.org/10.3390/pharmaceutics14030509

Theile, S., Johansen, J. S., Nielsen, D. L., Jensen, B. V., Hansen, C. P., Hasselby, J. P., Eiríksson, S. V., & Chen, I. M. (2022). A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC). Pharmaceutics, 14(3), 509. https://doi.org/10.3390/pharmaceutics14030509